Aliases:This biomarker is also known as:
- CD30 antigen ligand,
- tumor necrosis factor (ligand) superfamily, member 8,
- tumor necrosis factor ligand superfamily member 8,
- CD153 antigen,
- CD30 ligand,
TNFSF8, also known as CD30 ligand, is a cytokine belonging to the tumor necrosis factor (TNF) ligand family. TNFSF8 binds to TNFRSF8/CD30, a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. TNFSF8 has been shown to induce proliferation of T-cells. It also enhances cell proliferation of some lymphoma cell lines, and induces cell death and reduces cell proliferation of other lymphoma cell lines. There are two different isoforms encoded by two transcript variants.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
TNFSF8 variants may be involved in the etiology of lung cancer.
TNFSF8 is a member of the TNF ligand superfamily, which stimulates T-cell growth. Up-regulation of this protein correlates with proliferation in hematological malignancies. Further studies have shown possible involvement in susceptibility to lung cancer. TNFSF8 is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.
- The State of Molecular Biomarkers for the Early Detection of Lung Cancer.
- Association of a novel functional promoter variant (rs2075533 C>T) in the apoptosis gene TNFSF8 with risk of lung cancer--a finding from Texas lung cancer genome-wide association study.
- Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.